 Imara Inc NASDAQ: IMRA has announced a change to the primary endpoint for the Ardent Phase 2 trial of tovinontrine IMR-687 in sickle cell disease. Imara is a biopharmaceutical company focused on therapeutics for rare inherited genetic disorders of hemoglobin. 